| human | Q5 |
| P496 | ORCID iD | 0000-0003-3936-8032 |
| P1153 | Scopus author ID | 35402388700 |
| P734 | family name | Hasselbalch | Q35261552 |
| Hasselbalch | Q35261552 | ||
| Hasselbalch | Q35261552 | ||
| P735 | given name | Hans | Q632842 |
| Hans | Q632842 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q28553797 | A 7-Gene Signature Depicts the Biochemical Profile of Early Prefibrotic Myelofibrosis |
| Q53338106 | A der(18)t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycythemic myelofibrosis. |
| Q69105155 | A distinct subtype of idiopathic myelofibrosis with bone marrow features mimicking hairy cell leukemia: evidence of an autoimmune pathogenesis |
| Q34189794 | A highly sensitive quantitative real-time PCR assay for determination of mutant JAK2 exon 12 allele burden |
| Q37682689 | A nationwide population-based cross-sectional survey of health-related quality of life in patients with myeloproliferative neoplasms in Denmark (MPNhealthSurvey): survey design and characteristics of respondents and nonrespondents |
| Q30992878 | A new internet-based tool for reporting and analysing patient-reported outcomes and the feasibility of repeated data collection from patients with myeloproliferative neoplasms |
| Q83258186 | A novel immunohistochemical sequential multi-labelling and erasing technique enables epitope characterization of bone marrow pericytes in primary myelofibrosis |
| Q39403830 | A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia. |
| Q42551329 | A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis |
| Q53247635 | A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. |
| Q47690234 | A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. |
| Q43739631 | A possible role for STI571 in the treatment of idiopathic myelofibrosis |
| Q41882404 | A remarkable hematological and molecular response pattern in a patient with polycythemia vera during combination therapy with simvastatin and alendronate |
| Q38802882 | A retrospective analysis of the impact of treatments and blood counts on survival and the risk of vascular events during the course of polycythaemia vera. |
| Q47816393 | A role of NF-E2 in chronic inflammation and clonal evolution in essential thrombocythemia, polycythemia vera and myelofibrosis? |
| Q43237567 | A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process |
| Q36717896 | A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. |
| Q70162109 | Aberrations of chromosome 6 in 193 newly diagnosed untreated cases of chronic lymphocytic leukemia |
| Q42247181 | Activated platelets enhance IL-10 secretion and reduce TNF-α secretion by monocytes |
| Q44569638 | Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan |
| Q38706624 | Age-Related Macular Degeneration in Patients With Chronic Myeloproliferative Neoplasms |
| Q68129520 | Alcohol intolerance in the hypereosinophilic syndrome |
| Q45107227 | Anagrelide treatment in 52 patients with chronic myeloproliferative diseases |
| Q48313037 | Anemia is present years before myelodysplastic syndrome diagnosis: Results from the pre-diagnostic period. |
| Q81226465 | Angiogenesis in pulmonary hypertension with myelofibrosis |
| Q40157905 | Antecedent cardiovascular disease and autoimmunity in Philadelphia-negative chronic myeloproliferative neoplasms. |
| Q41713535 | Association of the blood eosinophil count with hematological malignancies and mortality |
| Q79734838 | B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study |
| Q36897408 | B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy the latest addition to an expanding family |
| Q73643443 | B-cell depletion with rituximab-a targeted therapy for Graves' disease and autoimmune thyroiditis |
| Q91817678 | B-cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferon-α2, or combination treatment |
| Q57788925 | Bone marrow histomorphology and JAK2 mutation status in essential thrombocythemia |
| Q51333593 | Characterization of blood donors with high haemoglobin concentration. |
| Q87297788 | Chronic inflammation and autoimmunity as risk factors for the development of chronic myelomonocytic leukemia? |
| Q38061746 | Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development? |
| Q51241783 | Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms. |
| Q45058582 | Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study |
| Q42221121 | Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state |
| Q61930297 | Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat |
| Q44541251 | Circulating hyaluronan in the myelofibrosis/osteomyelosclerosis syndrome and other myeloproliferative disorders |
| Q54008969 | Collagen metabolism and enzymes of the urokinase plasminogen activator system in chronic myeloproliferative disorders: correlation between plasma-soluble urokinase plasminogen activator receptor and serum markers for collagen metabolism. |
| Q41998667 | Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera |
| Q42426410 | Corrigendum to "Combination therapy with interferon and JAK1-2 inhibitor is feasible. Proof of concept with rapid reduction in JAK2V617F-allele burden in Polycythemia Vera" [Leuk. Res. Rep. 3 (2) (2014) 73-75]. |
| Q92996868 | Data-driven analysis of JAK2V617F kinetics during interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms |
| Q88009627 | Demonstrated Benefit of Continuous Interferon-Alpha-2b Therapy in Hairy Cell Leukemia. A Two-Year Follow-Up |
| Q33328174 | Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis. |
| Q36169641 | Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment |
| Q48228561 | Discordance between the cortisol response to insulin-hypoglycemia and 30-minute ACTH stimulation test in chronic alcoholic men. |
| Q37231416 | Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence. |
| Q33436570 | Effect of thrombopoietin-receptor agonists on circulating cytokine and chemokine levels in patients with primary immune thrombocytopenia (ITP). |
| Q79358236 | Elevated plasma levels of TIMP-1 correlate with plasma suPAR/uPA in patients with chronic myeloproliferative disorders |
| Q44148383 | Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera |
| Q44007100 | Eosinophilia in routine blood samples and the subsequent risk of hematological malignancies and death |
| Q53236154 | Eosinophilia in routine blood samples as a biomarker for solid tumor development - A study based on the Copenhagen Primary Care Differential Count (CopDiff) Database. |
| Q42339242 | Epigenetic changes in myelofibrosis: Distinct methylation changes in the myeloid compartments and in cases with ASXL1 mutations |
| Q54333652 | Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α. |
| Q40448136 | Extreme neutrophil granulocytosis in a patient with anaplastic large cell lymphoma of T-cell lineage. |
| Q54597002 | FLT3-mediated p38-MAPK activation participates in the control of megakaryopoiesis in primary myelofibrosis. |
| Q33397092 | Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents |
| Q43916592 | Frequent occurrence of anticardiolipin antibodies, Factor V Leiden mutation, and perturbed endothelial function in chronic myeloproliferative disorders |
| Q83796932 | High expression of carcinoembryonic antigen-related cell adhesion molecule (CEACAM) 6 and 8 in primary myelofibrosis |
| Q45149702 | High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden |
| Q44208224 | High rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms. |
| Q34171747 | Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders. |
| Q68073139 | Hypercalcemia in idiopathic myelofibrosis: modulation of calcium and collagen homeostasis by 1,25-dihydroxyvitamin D3 |
| Q48960781 | Hypothalamic-pituitary and thyroid function in chronic alcoholics with neurological complications |
| Q41414552 | Hypothesis: a possible role for interferon in the treatment of idiopathic myelofibrosis |
| Q40859828 | Idiopathic myelofibrosis--an update with particular reference to clinical aspects and prognosis |
| Q44667229 | Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis |
| Q50664354 | Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. |
| Q61698815 | Increase in circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN- |
| Q43605862 | Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count |
| Q39722432 | Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms |
| Q40808732 | Increased iron stores prolong the QT interval - a general population study including 20 261 individuals and meta-analysis of thalassaemia major. |
| Q74129093 | Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders |
| Q84114126 | Interferon alfa in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms |
| Q46636672 | Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis |
| Q69912609 | Interferon in myelofibrosis |
| Q87353766 | Interferon in polycythemia vera and related neoplasms. Can it become the treatment of choice without a randomized trial? |
| Q54245609 | Interferon-α induces marked alterations in circulating regulatory T cells, NK cell subsets, and dendritic cells in patients with JAK2V617F-positive essential thrombocythemia and polycythemia vera. |
| Q41313835 | Is thrombocytosis a valid indicator of advanced stage and high mortality of gynecological cancer? |
| Q42629080 | Lack of somatic mutations in the catalytic domains of CREBBP and EP300 genes implies a role for histone deacetylase inhibition in myeloproliferative neoplasms |
| Q46156541 | Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden |
| Q44837107 | Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha |
| Q34775393 | MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. |
| Q26775996 | MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives |
| Q41576528 | Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development |
| Q42133965 | Mediators of Inflammation in Myeloproliferative Neoplasms: State of the Art. |
| Q40959669 | Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera |
| Q57788892 | Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission |
| Q39237430 | Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib. |
| Q41325566 | Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms |
| Q48127316 | Molecular profiling as a novel tool to predict response to interferon-α2 in MPNs: The proof of concept in early myelofibrosis |
| Q84760917 | Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: identification of deregulated genes of significance for inflammation and immune surveillance |
| Q98632589 | Myeloproliferative blood cancers as a human neuroinflammation model for development of Alzheimer's disease: evidences and perspectives |
| Q38725723 | Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both |
| Q42847809 | Myeloproliferative neoplasms in five multiple sclerosis patients |
| Q92385638 | Neo-antigen specific memory T-cell responses in healthy individuals |
| Q77319931 | Non-invasive imaging of retinal blood flow in myeloproliferative neoplasms |
| Q67653780 | On the pathogenesis of angiogenesis in idiopathic myelofibrosis |
| Q39979643 | Optimal therapy for polycythemia vera and essential thrombocythemia: Preferred use of interferon therapy based on phase 2 trials |
| Q83408567 | Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? |
| Q57159202 | Perspectives on interferon-alpha in the treatment of Polycythemia vera and related Myeloproliferative neoplasms: minimal residual disease and cure? |
| Q38187674 | Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms. |
| Q53680800 | Perspectives on the increased risk of second cancer in patients with essential thrombocythemia, polycythemia vera and myelofibrosis. |
| Q37163590 | Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. |
| Q40081960 | Prevalence and clinical significance of neutropenia discovered in routine complete blood cell counts: a longitudinal study |
| Q92882962 | Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population |
| Q57788910 | Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow |
| Q37412790 | Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. |
| Q40408575 | Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). |
| Q33734256 | Risk of lymphoma and solid cancer among patients with rheumatoid arthritis in a primary care setting |
| Q33405127 | Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia |
| Q33365619 | Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura |
| Q33422507 | Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients. |
| Q44530765 | SU6668 in idiopathic myelofibrosis--a rational therapeutic approach targeting several tyrosine kinases of importance for the myeloproliferation and the development of bone marrow fibrosis and angiogenesis |
| Q63728939 | Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis |
| Q51608068 | Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms. |
| Q54157248 | Serum hyaluronan is increased in malignant lymphoma. |
| Q72138908 | Serum laminin P1 in idiopathic myelofibrosis and related diseases |
| Q69606775 | Serum markers for type IV collagen and type III procollagen in the myelofibrosis-osteomyelosclerosis syndrome and other chronic myeloproliferative disorders |
| Q41348010 | Smoking and philadelphia-negative chronic myeloproliferative neoplasms |
| Q38606278 | Smoking as a contributing factor for development of polycythemia vera and related neoplasms |
| Q57466753 | Smoking is associated with increased risk of myeloproliferative neoplasms: A general population-based cohort study |
| Q92244700 | Smoking, blood cells and myeloproliferative neoplasms: meta-analysis and Mendelian randomization of 2·3 million people |
| Q61698758 | Sorted peripheral blood cells identify CALR mutations in B- and T-lymphocytes |
| Q91523738 | Spontaneous T-cell responses against Arginase-1 in the chronic myeloproliferative neoplasms relative to disease stage and type of driver mutation |
| Q36398850 | Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential? |
| Q44059767 | Successful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietin |
| Q72488695 | Survival after a blood alcohol of 1127 mg/dl |
| Q38384255 | Survival of patients with chronic myeloproliferative neoplasms and new primary cancers: a population-based cohort study |
| Q40091659 | Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera. |
| Q33338419 | Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia. |
| Q61698772 | The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms |
| Q33774105 | The Copenhagen Primary Care Differential Count (CopDiff) database |
| Q28067986 | The Danish National Chronic Myeloid Neoplasia Registry |
| Q46931482 | The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype |
| Q79805830 | The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders |
| Q84545968 | The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis |
| Q26779929 | The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms |
| Q64336965 | The V617F and exon 9 mutations are shared immunogenic neoantigens in hematological malignancy |
| Q88895062 | The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms |
| Q51061525 | The platelet-cancer loop in myeloproliferative cancer. Is thrombocythemia an enhancer of cancer invasiveness and metastasis in essential thrombocythemia, polycythemia vera and myelofibrosis? |
| Q36462675 | The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. |
| Q90481351 | The red blood cell count and the erythrocyte sedimentation rate in the diagnosis of polycythaemia vera |
| Q38082073 | The role of cytokines in the initiation and progression of myelofibrosis. |
| Q33398815 | Thrombopoietin-receptor agonists in haematological disorders: the Danish experience |
| Q41809175 | Transcriptional profiling of whole blood identifies a unique 5-gene signature for myelofibrosis and imminent myelofibrosis transformation |
| Q80061323 | Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion |
| Q71378079 | Urinary free cortisol during pregnancy |
| Q50747615 | V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. |
| Q35705470 | WHO classification 2008 of myeloproliferative neoplasms: a workshop learning effect--the Danish experience |
| Q59194482 | Whole blood assay for NK activity in splenectomized and non-splenectomized hairy cell leukemia patients during IFN-α-2b treatment |
| Q34514329 | Whole blood transcriptional profiling reveals deregulation of oxidative and antioxidative defence genes in myelofibrosis and related neoplasms. Potential implications of downregulation of Nrf2 for genomic instability and disease progression |
| Q85862955 | Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis |
| Q83742042 | Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis |
| Q36562094 | Whole-exome sequencing and genome-wide methylation analyses identify novel disease associated mutations and methylation patterns in idiopathic hypereosinophilic syndrome |
| Q45884600 | World Health Organization-defined classification of myeloproliferative neoplasms: morphological reproducibility and clinical correlations--the Danish experience |
Search more.